MedPath

Nelarabine

These highlights do not include all the information needed to use NELARABINE INJECTION safely and effectively. See full prescribing information for NELARABINE INJECTION. NELARABINE injection, for intravenous useInitial U.S. Approval: 2005

Approved
Approval ID

8cb23281-93ca-40b8-b8e0-c57dd4298322

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 22, 2023

Manufacturers
FDA

Zydus Pharmaceuticals USA Inc.

DUNS: 156861945

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Nelarabine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70710-1839
Application NumberANDA215037
Product Classification
M
Marketing Category
C73584
G
Generic Name
Nelarabine
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 22, 2023
FDA Product Classification

INGREDIENTS (5)

HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
NELARABINEActive
Quantity: 5 mg in 1 mL
Code: 60158CV180
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Nelarabine - FDA Drug Approval Details